Insmed rises on late-stage trial results for Arikayce for lung infection
Source: SeekingAlpha
2026-03-23 12:04:59 ET
More on Insmed
- Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
- Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Insmed Incorporated 2025 Q4 - Results - Earnings Call Presentation
- Insmed outlines $1B-plus BRINSUPRI revenue target for 2026 while advancing pipeline and ARIKAYCE expansion
- Insmed misses Q4 earnings estimates
Read the full article on Seeking Alpha
For further details see:
Insmed rises on late-stage trial results for Arikayce for lung infection
Insmed Incorporated
NASDAQ: INSM
INSM Trading
5.34% G/L:
$147.90 Last:
827,440 Volume:
$140 Open:
INSM Latest News
March 23, 2026 07:00:00 am
Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
February 19, 2026 07:00:00 am
Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
INSM Stock Data
$31,647,650,065
206,875,265
0.18%
273
N/A
Biotechnology & Life Sciences
Healthcare
US
Bridgewater
